We are live on
!
Find out more
KCM
Kingdon Capital Management Portfolio holdings
AUM
$911M
1-Year Est. Return
51.11%
This Fund
S&P 500
This Quarter
Est. Return
-1.66%
1 Year Est. Return
+51.11%
3 Year Est. Return
+185.44%
5 Year Est. Return
+284.29%
10 Year Est. Return
+2,022.7%
AUM
$847M
AUM Growth
-$171M
(-17%)
Cap. Flow
-$141M
Cap. Flow
% of AUM
-16.68%
Top 10 Holdings %
Top 10 Hldgs %
40.65%
Holding
87
New
19
Increased
18
Reduced
19
Closed
26
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Marathon Petroleum
MPC
|
+$26.6M |
| 2 |
Crown Holdings
CCK
|
+$25M |
| 3 |
Motorola Solutions
MSI
|
+$21M |
| 4 |
AERI
Aerie Pharmaceuticals
AERI
|
+$18.6M |
| 5 |
Union Pacific
UNP
|
+$17.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Freeport-McMoran
FCX
|
+$36.5M |
| 2 |
Boston Scientific
BSX
|
+$22.9M |
| 3 |
Coty
COTY
|
+$22.2M |
| 4 |
Middleby
MIDD
|
+$20.7M |
| 5 |
Norfolk Southern
NSC
|
+$19.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.84% |
| 2 | Consumer Discretionary | 13.83% |
| 3 | Technology | 12.45% |
| 4 | Industrials | 10.08% |
| 5 | Communication Services | 8.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Medifast
MED
$145M
| $13.6M | 1.6% |
+130,956
| New | +$14.1M |
|
|
FLXN
27
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $13.5M | 1.59% |
983,924
+55,000
| +6% | +$653K |
|
28
Rapid7
RPD
$720M
| $13.4M | 1.58% |
294,469
+143,644
| +95% | +$8.07M |
|
29
Zebra Technologies
ZBRA
$17.6B
| $13.3M | 1.57% |
64,382
-56,665
| -47% | -$11.4M |
|
30
CALL
Walt Disney
DIS
$170B
| $13M | 1.54% |
100,000
+40,000
| +67% | +$5.53M |
|
31
Nomad Foods
NOMD
$1.66B
| $12.4M | 1.47% |
605,919
+10,720
| +2% | +$229K |
|
32
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.92B
| $12.2M | 1.44% |
160,000
-240,000
| -60% | -$19.9M |
|
|
IAA
33
DELISTED
IAA, Inc. Common Stock
IAA
| $12.1M | 1.42% |
+288,838
| New | +$13M |
|
34
WillScot Mobile Mini Holdings
WSC
$4.83B
| $11.4M | 1.35% |
731,300
-75,176
| -9% | -$1.13M |
|
|
AGN
35
DELISTED
Allergan plc
AGN
| $10.1M | 1.2% |
60,216
+10,216
| +20% | +$1.66M |
|
36
Heron Therapeutics
HRTX
$96.8M
| $9.36M | 1.11% |
505,729
-325,092
| -39% | -$5.98M |
|
|
SGEN
37
PUT
DELISTED
Seagen Inc. Common Stock
SGEN
| $8.54M | 1.01% |
+100,000
| New | +$7.33M |
|
|
ARQL
38
DELISTED
Arqule Inc
ARQL
| $8.4M | 0.99% |
1,171,352
+185,435
| +19% | +$1.74M |
|
|
39
Walt Disney
DIS
$170B
| $8.36M | 0.99% |
64,122
-31,701
| -33% | -$4.38M |
|
|
GTYH
40
DELISTED
GTY Technology Holdings, Inc. Common Stock
GTYH
| $7.52M | 0.89% |
1,200,000
| – | – |
|
|
CARM
41
DELISTED
Carisma Therapeutics
CARM
| $7.2M | 0.85% |
307,766
-543
| -0.2% | -$12.7K |
|
|
ATNX
42
DELISTED
Athenex, Inc. Common Stock
ATNX
| $6.53M | 0.77% |
26,819
-1,578
| -6% | -$516K |
|
43
PTC Therapeutics
PTCT
$5.77B
| $6.19M | 0.73% |
183,119
+45,900
| +33% | +$2M |
|
44
Lattice Semiconductor
LSCC
$19.6B
| $5.98M | 0.71% |
327,277
-341,191
| -51% | -$6.25M |
|
|
TVRD
45
Tvardi Therapeutics
TVRD
$19M
| $5.15M | 0.61% |
7,828
+2,259
| +41% | +$1.88M |
|
46
Sol-Gel Technologies
SLGL
$276M
| $5.14M | 0.61% |
57,138
+26,079
| +84% | +$2.35M |
|
47
Great Elm Group
GEG
$67.4M
| $4.65M | 0.55% |
1,267,030
| – | – |
|
|
BHVN
48
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $4.17M | 0.49% |
+100,000
| New | +$4.22M |
|
|
AERI
49
CALL
DELISTED
Aerie Pharmaceuticals
AERI
| $3.84M | 0.45% |
+200,000
| New | +$4.58M |
|
|
MTEM
50
DELISTED
Molecular Templates, Inc.
MTEM
| $3.57M | 0.42% |
36,104
+1,718
| +5% | +$160K |
|
Similar funds
GC
ICP
NAM
SAA
GIG
SI
PAMI
BDP
Kingdon Capital Management's Q3 2019 Portfolio in Review
As of Q3 2019, Kingdon Capital Management held 87 positions worth $847M, down 17% from $1.02B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Kingdon Capital Management withdrew a net $141M in Q3 2019, closing 26 positions and reducing 19 holdings. Its most notable exit was Freeport-McMoran, an estimated $36.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 25% a quarter earlier, followed by Consumer Discretionary and Technology.
Against the trend, Kingdon Capital Management opened a new position in Marathon Petroleum worth $30.6M.
- Kingdon Capital Management's largest Q3 2019 buy was Marathon Petroleum: 504,377 shares worth $30.6M.
- Kingdon Capital Management added most to Rapid7 in Q3 2019, an estimated $8.07M increase.
- Kingdon Capital Management's biggest Q3 2019 reduction was Zebra Technologies, cutting an estimated $11.4M.
- Kingdon Capital Management fully exited Freeport-McMoran in Q3 2019, selling an estimated $36.5M.
- Kingdon Capital Management's ten largest holdings make up 41% of its $847M portfolio in Q3 2019.
- Kingdon Capital Management opened 19 new positions and closed 26 in Q3 2019.
- Kingdon Capital Management's portfolio value fell 17% quarter-over-quarter to $847M.
Based on Kingdon Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.